Privately held regenerative medicine firm Histogen announces that it has granted exclusive rights to collaboration partner Allergan (AGN -0.8%) to incorporate and commercialize its cell conditioned media (CCM) technology in microabrasion therapies and new Histogen intellectual property in the aesthetic field.
The companies inked their original agreement in
2017 when Allergan acquired exclusive rights to develop and
commercialize CCM to healthcare providers in the aesthetic field. It
subsequently in-licensed the rights to CCM in new distribution channels
like digital platforms, health spas and salons.
Related ticker: AbbVie (ABBV -2.2%)
https://seekingalpha.com/news/3536406-allergan-expands-partnership-histogen
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.